Apatinib (YN968D1)

Catalog No. A11407

Apatinib (YN968D1)是一种酪氨酸激酶抑制剂，可选择性抑制血管内皮生长因子受体2（VEGFR2，也称为KDR），后者可抑制VEGF介导的内皮细胞迁移和增殖，从而阻止肿瘤组织中新血管的形成。

Product Citations

Wonjin Park, .et al. Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice, Biomed Pharmacother, 2021, Feb;134:111110 PMID: 33338749
Majid Momeny, .et al. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells, Sci Rep, 2017, 7: 45954 PMID: 28383032

Technical details

Catalog Num	A11407
M. Wt	493.6
Formula	C25H27N5O4S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	811803-05-1
Synonyms
SMILES	CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4

Biological Activity

Targets

Target	Value
VEGFR2	IC50: 1nM
RET	IC50: 13nM
c-Kit	IC50: 429nM
c-Src	IC50: 530nM
PDGFRα	IC50: >1μM
EGFR	IC50: >10μM
HER2	IC50: >10μM
FGFR1	IC50: >10μM

Solubility *

In vitro	DMSO	77 mg/mL (193.72 mM)
	Water	Insoluble
	Ethanol	10 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	20.26 mL	101.3 mL	202.59 mL
0.5 mM	4.05 mL	20.26 mL	40.52 mL
1 mM	2.03 mL	10.13 mL	20.26 mL
5 mM	0.41 mL	2.03 mL	4.05 mL

*The above data is based on the productmolecular weight 493.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.